Oncolinx
Boston
About Oncolinx
Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy. The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world’ concurrently developing ADCs across 30 different cancer indications. Oncolinx aims to enter clinical trials with a partnered program in mid-2017.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $1.1M
- Funding stage: Seed
- Last round: Seed (Oct 2016)
- Website: oncolinx.com
- Phone: +44 2035141013
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/oncolinx-136389 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.